Singapore: Israel-based Oramed Pharmaceuticals, a developer of oral drug delivery systems, has announced receiving two additional patent approvals for its platform Protein Oral Delivery (POD) technology in Japan and Canada. Both granted patents are titled "Methods and Compositions for Oral Administrations of Proteins."

Oramed's proprietary POD technology is based on over 30 years of research by the scientists at Jerusalem's Hadassah Medical Center. Addressing the obstacles to the oral administration of small protein (peptide) molecules, POD technology both protects and enhances protein delivery and absorption via the digestive system and into the bloodstream. In this way, Oramed's POD technology can be used to develop oral alternatives for a number of today's injectable therapies.

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006 and based on Oramed's platform POD technology, Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating phase II clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the US Food and Drug Administration.